Page 12 - TAKLIMAT Bidang Pembangunan Manusia dan kebudayaan

Judul : BPOM Aims to Start Indigenous Vaccine Production by 2022 Second Half

Nama Media : tempo.co

Tanggal : 30 Desember 2021

Halaman/URL:https://en.tempo.co/read/1544671/bpom-aims-to-start-indigenous-
vaccine-production-by-2022-second-half

Tipe Media : Online

TEMPO.CO, Jakarta - Head of the National

Agency of Drug and Food Control (BPOM),
Penny Lukito, has said that the agency is
aiming to start production of the Red and
White vaccine in the second half of 2022.

“The Red and White vaccine (developed)
from the collaboration between Airlangga University and PT. Biotis is currently in
production for clinical trials. The clinical trials will commence soon. We are targeting
the production to start in the second half of 2022,” she informed during a media
briefing on Wednesday.

Meanwhile, the production of the vaccine developed by Bio Farma and Baylor
College Medicine is also targeted to start in the second half of 2022, she added.

She said the agency will soon issue emergency-use authorization (EUA) for booster
vaccines.

"Currently, vaccines that are in the registration process to be used as boosters are

Pfizer, AstraZeneca, Zlifivax, and CoronaVac or Biofarma’s COVID-19 vaccine, while
the Sinopharm vaccine is still in the pre-registration process," she added.

Meanwhile, BPOM has so far permitted Favipiravir, Remdesivir, and Regdanvimab
for emergency use.

"After the issuance of the emergency-use authorization, we carry out post-market
surveillance to ensure the drugs are being distributed properly, as well as (conduct)
pharmacovigilance of adverse events following immunization or AEFIs," she
explained.

The Indonesian government launched a nationwide vaccination program on January
13, 2021, in a bid to boost immunity against COVID-19.